GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Orexo AB (OSTO:ORX) » Definitions » Beneish M-Score

Orexo AB (OSTO:ORX) Beneish M-Score : -2.77 (As of May. 05, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Orexo AB Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.77 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Orexo AB's Beneish M-Score or its related term are showing as below:

OSTO:ORX' s Beneish M-Score Range Over the Past 10 Years
Min: -3.02   Med: -2.73   Max: 1.39
Current: -2.77

During the past 13 years, the highest Beneish M-Score of Orexo AB was 1.39. The lowest was -3.02. And the median was -2.73.


Orexo AB Beneish M-Score Historical Data

The historical data trend for Orexo AB's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orexo AB Beneish M-Score Chart

Orexo AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.78 -2.85 -2.42 -2.44 -2.77

Orexo AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.44 -2.94 -2.70 -2.83 -2.77

Competitive Comparison of Orexo AB's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Orexo AB's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orexo AB's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orexo AB's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Orexo AB's Beneish M-Score falls into.



Orexo AB Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Orexo AB for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8039+0.528 * 0.9708+0.404 * 1.2455+0.892 * 1.0231+0.115 * 0.8545
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8997+4.679 * -0.03763-0.327 * 1.1157
=-2.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was kr218.1 Mil.
Revenue was 166 + 156.1 + 157.7 + 158.8 = kr638.6 Mil.
Gross Profit was 145.9 + 133.3 + 140.5 + 130.1 = kr549.8 Mil.
Total Current Assets was kr458.9 Mil.
Total Assets was kr786.6 Mil.
Property, Plant and Equipment(Net PPE) was kr105.6 Mil.
Depreciation, Depletion and Amortization(DDA) was kr76.9 Mil.
Selling, General, & Admin. Expense(SGA) was kr369.3 Mil.
Total Current Liabilities was kr263.2 Mil.
Long-Term Debt & Capital Lease Obligation was kr452.9 Mil.
Net Income was -18.6 + -33.3 + -12.6 + -63.9 = kr-128.4 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = kr0.0 Mil.
Cash Flow from Operations was -2.6 + -21.9 + -12.7 + -61.6 = kr-98.8 Mil.
Total Receivables was kr265.2 Mil.
Revenue was 156 + 161 + 147.8 + 159.4 = kr624.2 Mil.
Gross Profit was 130.2 + 133 + 126.6 + 131.9 = kr521.7 Mil.
Total Current Assets was kr735.5 Mil.
Total Assets was kr1,109.0 Mil.
Property, Plant and Equipment(Net PPE) was kr122.1 Mil.
Depreciation, Depletion and Amortization(DDA) was kr68.7 Mil.
Selling, General, & Admin. Expense(SGA) was kr401.2 Mil.
Total Current Liabilities was kr385.9 Mil.
Long-Term Debt & Capital Lease Obligation was kr519.0 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(218.1 / 638.6) / (265.2 / 624.2)
=0.341528 / 0.424864
=0.8039

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(521.7 / 624.2) / (549.8 / 638.6)
=0.83579 / 0.860946
=0.9708

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (458.9 + 105.6) / 786.6) / (1 - (735.5 + 122.1) / 1109)
=0.282354 / 0.226691
=1.2455

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=638.6 / 624.2
=1.0231

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(68.7 / (68.7 + 122.1)) / (76.9 / (76.9 + 105.6))
=0.360063 / 0.42137
=0.8545

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(369.3 / 638.6) / (401.2 / 624.2)
=0.578296 / 0.642743
=0.8997

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((452.9 + 263.2) / 786.6) / ((519 + 385.9) / 1109)
=0.910374 / 0.81596
=1.1157

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-128.4 - 0 - -98.8) / 786.6
=-0.03763

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Orexo AB has a M-score of -2.77 suggests that the company is unlikely to be a manipulator.


Orexo AB Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Orexo AB's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Orexo AB (OSTO:ORX) Business Description

Traded in Other Exchanges
Address
Virdings alle 32 A, P.O. Box 303, Uppsala, SWE, 75105
Orexo AB has operations in Sweden and the United States. Operations are monitored and presented in the segments US Pharma, Digital Therapeutics (DTx) and HQ & Pipeline. The majority is from the US Pharma segment. Geographically, the majority is derived from the United States. US Pharma includes the commercialization of fully owned pharmaceuticals in the United States market. Digital Therapeutics include the commercialization of Orexo's groundbreaking evidence-based digital therapeutics, mainly in the United States market, which is in an early development stage. HQ &Pipeline include the Development of pharmaceuticals performed at Orexo's headquarters in Uppsala, Sweden.

Orexo AB (OSTO:ORX) Headlines

No Headlines